Ambit Biosciences presents data from Phase 2 ACE study of quizartinib for treatment of AML

Ambit Biosciences Corporation announced today data from the Phase 2 ACE study of quizartinib , a FLT3 inhibitor, were featured in multiple presentations at the 18th Congress of the European Hematology Association in Data presented included analyses of patients with relapsed or refractory acute myeloid leukemia from a Phase 2 clinical trial of ... (more)

http://www.news-medical.net/news/20130627/Ambit-Biosciences-presents-data-from-Phase-2-ACE-study-of-quizartinib-for-treatment-of-AML.aspx